Star Rating for Biosimilars Act

Summary

Star Rating for Biosimilars Act This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management. The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 8 October 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

2. 8 October 2019

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

3. 8 October 2019

   Introduced

   Introduced in House

   Source: IntroReferral

4. 8 October 2019

   Introduced

   Introduced in House

   Source: IntroReferral

5. 9 October 2019

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

6. 18 October 2019

   Introduced

   Sponsor introductory remarks on measure. (CR H8232)

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in House · 8 October 2019 · Download file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 8 October 2019

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 8 October 2019

  ViewDownloadOpen at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

• Introduced in House

  summary · EN · 8 October 2019

  Open at official source

  Leesvertaling

  Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

  Vertaal naarNL · DutchDE · GermanFR · FrenchES · SpanishIT · ItalianPL · PolishPT · PortugueseSV · SwedishDA · DanishFI · FinnishEL · GreekCS · CzechHU · HungarianRO · RomanianBG · BulgarianHR · CroatianSK · SlovakSL · SlovenianLT · LithuanianLV · LatvianET · EstonianGA · IrishMT · Maltese

  Vertaal document

  Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

• Rep. Tonko, Paul [D-NY-20] · D · Sponsor
• Rep. Gibbs, Bob [R-OH-7] · R · Sponsor
• · hsif00 · Standing
• · hswm00 · Standing

Related records

• related to → Elijah E. Cummings Lower Drug Costs Now Act
• related to → Prescription Drug Pricing Reduction Act of 2019
• related to → Star Rating for Biosimilars Act
• related to ← Prescription Drug Pricing Reduction Act of 2020